



## **Nkarta to Participate in November Investor Conferences**

October 30, 2025

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conferences next month:

### **Stifel 2025 Healthcare Conference**

November 12, 2025

10:40 a.m. ET – fireside chat

### **TD Cowen's Immunology & Inflammation Summit**

November 13, 2025

5 p.m. ET – fireside chat

A simultaneous webcast of the event will be available on the Investors section of Nkarta's website, [www.nkartatx.com](http://www.nkartatx.com), and a replay will be archived on the website for approximately 90 days.

### **About Nkarta**

Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company's website at [www.nkartatx.com](http://www.nkartatx.com).

### **Nkarta Media/Investor Contact:**

Nadir Mahmood

Nkarta, Inc.

[nmahmood@nkartatx.com](mailto:nmahmood@nkartatx.com)